Podcasts about diabetes technology

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

At ESC 2025, a pair of presentations highlighted the ongoing debate over cardiovascular risk reduction with semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), yielding conflicting signals that clinicians will need to interpret carefully. In this special edition episode, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, explore these studies: SURMOUNT-5 and STEER. A post hoc analysis of SURMOUNT-5 compared the 10-year predicted CV risk reduction between the 2 agents. Using the Framingham Risk Calculator in 751 patients with obesity, tirzepatide was associated with greater benefit than semaglutide. From baseline risks of ~9%, tirzepatide was projected to lower absolute 10-year CV risk by 2.4% (23% relative reduction) compared with 1.4% (13% relative reduction) for semaglutide. Investigators attributed the advantage largely to greater weight and glycemic reductions. In contrast, the STEER study, a real-world analysis of more than 21,000 patients with a mean follow-up of 8.5 months, suggested semaglutide was associated with lower rates of major adverse cardiovascular events (MACE) than tirzepatide. Semaglutide users had a 29% risk reduction in nonfatal MI, nonfatal stroke, or CV death compared with tirzepatide. Limitations included short follow-up, relatively few CV events, and the inherent confounding of observational data. Both Isaacs and Bellini emphasized that while weight and glycemic improvements with tirzepatide appear robust, CV benefits may be molecule-specific. The ongoing SURPASS-CVOT, comparing tirzepatide with dulaglutide, should provide more clarity when full data are released at EASD. In the interim, the hosts advised prescribing based on labeled indications supported by randomized outcomes data—semaglutide for CV and kidney risk reduction, tirzepatide for obesity and sleep apnea—while awaiting definitive trial results. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. References: Mamas M. SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction .Presented at the European Society of Cardiology (ESC) Congress 2025. Madrid, Spain. August 29- September 1, 2025. Novo Nordisk. Novo Nordisk's Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease. Novo Nordisk. Published August 31, 2025. Accessed September 5, 2025. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916422

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, highlight key advancements in diabetes management, particularly in continuous glucose monitoring (CGM) during pregnancy and the anticipated future of continuous ketone monitoring, from Association of Diabetes Care and Education Specialists (ADCES) 2025 annual meeting. 00:00:00 Introduction 00:00:30 Continuous Glucose Monitoring in Pregnancy 00:04:59 Stello versus Finger Sticks for Insulin Dosing 00:13:43 Innovative Presentations at ADCES 00:14:36 Ketone Monitoring 00:18:15 Product Theaters and Gamification at ADCES

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, shared highlights on several major insulin delivery updates making waves at recent meetings. 00:00:00 Introduction 00:00:20 Pivot by Modular Medical 00:07:13 Medtronic's Partnership with Abbott - the Instinct Sensor 00:09:04 Tandem's One-Handed Insert 00:10:14 Tandem's Mobi Patch Pump

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, explore the latest milestone for semaglutide (Wegovy): US Food and Drug Administration (FDA) approval for the treatment of metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced fibrosis. They frame the decision as a breakthrough in addressing a disease that affects an estimated 6% of the U.S. population, with even higher prevalence among individuals with type 2 diabetes and obesity. MASH, often underrecognized and asymptomatic in its early stages, carries serious long-term consequences, including cirrhosis, hepatocellular carcinoma, liver transplantation, and premature mortality. 00:00:00 Introduction 00:00:32 Semaglutide (Wegovy) Approval 00:06:31 Novo Nordisk Announces Ozempic Price Change 00:08:21 Compounding Pharmacies 00:10:57 The Future of Semaglutide

On July 31, 2025, Eli Lilly and Company announced topline data from the SURPASS‑CVOT trial comparing tirzepatide (Mounjaro) to dulaglutide (Trulicity) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD). According to the data, tirzepatide met the primary non‑inferiority endpoint for 3-point major adverse cardiovascular events (MACE) (hazard ratio [HR], 0.92; 95.3% CI, 0.83 to 1.01), while also showing additional benefits in A1C, weight reduction, renal preservation, and a 16% reduction in all‑cause mortality (HR, 0.84; 95.0% CI, 0.75 to 0.94). In the latest episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, unpacked the top-line results of the SURPASS-CVOT trial. Eli Lilly and Company owns both drugs, which belong to the incretin class, but tirzepatide is a dual GIP/GLP-1 receptor agonist, while dulaglutide is a GLP-1 RA. The trial included over 13,000 adults with type 2 diabetes and either established cardiovascular disease or at high risk. During a median follow-up of 4.5 years, the primary endpoint, which was a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, was reduced by 8% in the tirzepatide group relative to dulaglutide. However, the result did not reach statistical superiority due to the confidence interval crossing unity. Isaacs and Bellini also highlighted significantly greater A1c (-1.73% vs -0.9%) and weight loss (12% vs 4.95%) with tirzepatide. Additional prespecified analyses comparing data with the placebo-controlled REWIND trial suggest tirzepatide could offer up to 28% MACE and 39% mortality risk reduction compared to theoretical placebo—findings that hint at broader cardiometabolic benefit. Before concluding, hosts speculated about the potential subgroup analyses of interest for the trial, including heart failure and renal outcomes, as well as a brief discussion around Eli Lilly and Company's intent to submit a regulatory application for a cardiovascular indication before the close of 2025. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. References: Eli Lilly and Company. Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease. July 31, 2025. Accessed July 31, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated

On this episode of the Huddle, Kelly Postiglione Cook, RN, MSN, ANP-BC, CDCES, BC-ADM, and Sean Oser, MD, MPH, CDCES have a conversation about the importance of utilizing automated insulin delivery systems, like the iLet bionic pancreas, more widely in primary care. They provide insight into a study that evaluated the success of implementing use of the iLet bionic pancreas in a primary care setting, how the results illustrated that this technology can be more widely utilized in these settings, and the role diabetes care and education specialists can play in this work.This episode is sponsored by Beta Bionics. Episode References: Bionic Pancreas Research Group. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med 2022;387:1161-1172 DOI: 10.1056/NEJMoa2205225 Russell SJ, Selagamsetty R, Damiano E. Real-world efficacy of the iLet bionic pancreas in adults and children during the first eighteen months of commercial availability. Presented at the American Diabetes Association 85th Scientific Sessions, June 20-23, 2025, Chicago, IL.   Oser SM, Putman MS, Russel SJ, et al. Assessing the iLet Bionic Pancreas deployed in primary care and via telehealth: a randomized clinical trial. Clin Diabetes 2025; cd240104. https://doi.org/10.2337/cd24-0104 Oser C, Parascando JA, Kostiuk M, et al. Experiences of people with type 1 diabetes using the iLet bionic pancreas in primary care: A qualitative analysis. Clin Diabetes 2024 https://doi.org/10.2337/cd24-0060.  Sulik B, Postiglione Cook K, MacLeod J. Meals no longer need to be math problems: Shifting from precise carbohydrate counting to a continuum of carbohydrate awareness as automated insulin delivery advances. Diabetes Technology and Obesity Medicine 2025;1(1):79-83. DOI: 10.1089/dtom.2025.0010.  Resources:Learn more about Beta Bionics here: https://www.betabionics.com/Explore the latest in diabetes technology on danatech: danatech l Diabetes Technology Education for Healthcare ProfessionalsLearn more about a two-part course on integrating diabetes technology into primary care, put on through the collaboration of AANP and ADCES:Part 1: Integrating Diabetes Technology into Primary Care Part 1: Overview and Clinical ScenariosPart 2: Integrating Diabetes Technology into Primary Care Part 2: Interactive Case StudiesDive deeper into how diabetes technology can be incorporated into primary care on another recent episode of The Huddle featuring Kathryn Evans Kreider DNP, FNP-BC, BC-ADM, FAANP: https://thehuddle.simplecast.com/episodes/embracing-diabetes-technology-in-primary-care Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives! In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, recapped highlights from the 2025 Endocrine Society annual meeting. They spotlighted advances, controversies, and ongoing unmet needs in type 1 diabetes care. 00:00:00 Intro 00:00:40 GLP-1 RAs in type 1 diabetes 00:05:50 Tirzepatide in type 1 diabetes 00:08:32 Cardioprotective therapies in type 1 diabetes 00:12:17 Type 1 diabetes Barbie and public education

In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, sit down with Carol Levy, MD, director of the Mount Sinai Diabetes Center and Type 1 Diabetes Clinical Research, to discuss the upcoming T1D Pregnancy and Me – or PRAM T1D – clinical study. Enrollment for T1D Pregnancy & Me is currently open. Interested listeners can enroll at https://www.mountsinai.org/clinical-trials/t1d-pregnancy-me. 00:00:00 Introduction 00:01:43 The "why" behind the trial 00:04:24 The structure of the study 00:07:37 Will maternal outcomes be collected? 00:08:12 Can patients enroll themselves in this trial? 00:12:40 No devices will be excluded 00:15:20 Dividing data based on first versus later pregnancies 00:18:14 Will you continue to enroll after the first 500?

In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, continue their recap of ADA's 2025 Scientific Sessions, spotlighting 3 more of the top clinical trials focused on obesity and type 2 diabetes. 00:00:00 Intro 00:00:31 BELIEVE Trial 00:08:11 Phase 2 Maritide Trial 00:17:12 CATALYST-2

In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, recap some of the biggest clinical trials presented at the American Diabetes Association (ADA) 2025 conference in Chicago, Illinois. 00:00 Introduction 2:04 The Vertex Trial 6:57 The T1D Trial 15:23 The Achieve 1 Trial

This edWeb podcast is sponsored by Diabetes Network of Arizona.The webinar recording can be accessed here.This edWeb podcast builds understanding and empowers school staff to confidently support students with type 1 diabetes. Learning objectives include:Recognize the signs of high and low blood sugarUnderstand the role of diabetes technology in the classroomLearn how to support students in academic and physical activitiesPromote empathy, independence, and safe carePresenters from the Diabetes Network of Arizona discuss the topics of:“Why I might need to leave class”“Yes, I can eat that”“Sports, snacks, and safety”“What I wish you knew”Listen to this session to gain real insight, practical tools, and communication tips to create a supportive learning environment. Be the adult your students with diabetes trust. This edWeb podcast is of interest to K-12 teachers, school leaders, and district leaders.Learn more about viewing live edWeb presentations and on-demand recordings, earning CE certificates, and using accessibility features.

Join clinical experts Cheryl Rosenfeld, DO, FACE, FACP, FSVM, ECNU, Madhuri M. Vasudevan, MD, MPH, FACE, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, to learn how the AACE Patient Journey of Diabetes Technology supports people with diabetes in navigating their treatment options with confidence. This patient-friendly resource, developed from AACE clinical guidelines and reviewed by Diabetes Sisters, a leading patient advocacy organization, provides clear and accurate information on diabetes technologies, from glucose monitors to insulin delivery devices. The experts also highlight how members of the endocrine care team are using this tool to empower people with diabetes to manage their journey. This episode is brought to you with the support of Abbott, Novo Nordisk, Medtronic, and Vertex.

In this special episode recorded at 85th Scientific Sessions of the American Diabetes Association (ADA 2025), hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, take a deep dive into the REDEFINE 1 and REDEFINE 2 trials with trial investigators W. Timothy Garvey, MD, of University of Alabama at Birmingham, and Melanie Davies, MD, of the University of Leicester. REDEFINE 1 was a 68-week, phase 3a trial enrolling over 3400 adults without diabetes but with obesity or overweight and at least one comorbidity. Participants received once-weekly CagriSema, semaglutide alone, cagrilintide alone, or placebo alongside lifestyle intervention. Key outcome: CagriSema led to a mean weight loss of 20.4%, vs 3.0% with placebo. Over 50% of participants on CagriSema reached a non-obese BMI. Gastrointestinal side effects were common (80%), but mostly mild to moderate. REDEFINE 2 enrolled 1206 adults with type 2 diabetes and overweight or obesity, randomized to CagriSema or placebo for 68 weeks. Key outcome: CagriSema led to 13.7% mean weight loss, vs 3.4% with placebo. 73.5% achieved an HbA1c ≤6.5% vs 15.9% on placebo. Significant improvements were seen across all weight loss and glycemic endpoints. The speakers also highlight the agent's favorable side effect profile, flexibility in real-world dosing, and benefits in body composition and physical function. Garvey emphasizes the shift toward complication-centric obesity care, underscoring the need for clinician-guided treatment beyond online prescription models. The conversation closes with a look ahead to REDEFINE 3—a cardiovascular outcomes trial including patients with and without diabetes—and other ongoing studies in the REDEFINE and REIMAGINE trial programs. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Relevant disclosures for Garvey include Boehringer-Ingelheim, Novo Nordisk, Eli Lilly and Company, Merck & Co., Inc., Alnylam Pharmaceuticals, Inc., Fractyl Health, Inc., Inogen, Epitomee, Pfizer Inc., and Neurovalens. Relevant disclosures for Davies include Abbie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, GSK, Novo Nordisk, Pfizer, Regeneron, Roche, Sanofi, and Zealand Pharma. References: Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. Published online June 22, 2025. doi: 10.1056/NEJMoa2502081 Davies MJ, Bajaj HS, Broholm C. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England Journal of Medicine. Published online June 22, 2025. doi: 10.1056/NEJMoa2502082

In this special episode recorded at 85th Scientific Sessions of the American Diabetes Association (ADA 2025), hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, welcome Kevin Sayer, chief executive officer of Dexcom, for a candid conversation about the evolving landscape of continuous glucose monitoring (CGM). From Dexcom's origins to the latest updates on G7 and the emerging Stelo app, the discussion traces the company's journey and innovation roadmap. Sayer reflects on how sharing real-time glucose data transformed the diabetes management experience—making life safer not just for children but also for adults living independently, caregivers, and entire family networks. Dexcom's emphasis on data transparency has laid the groundwork for a broader shift toward individualized care, especially for those with type 2 diabetes. The episode dives into Dexcom's growing footprint in type 2 diabetes management, with expanded coverage across the nation's three largest pharmacy benefit managers. Sayer emphasizes that CGM is not just about preventing hypoglycemia in insulin users anymore—it's a behavioral and educational tool. Patients can now “see” the impact of food choices, physical activity, and medication adherence in real time, prompting lifestyle changes that might otherwise take years of trial-and-error clinical encounters. The hosts also explore the integration of AI-powered features like food recognition, enhancements in the Stelo app for wellness tracking, and the implications of new CGM algorithms as G7 expands to 15-day wear. Sayer addresses the unique needs of people with and without diabetes and the regulatory constraints in tailoring CGM algorithms to specific use cases. In a lighter moment, Sayer shares his enthusiasm for Dexcom's public-facing campaigns, including recent collaborations with Lance Bass and Nick Jonas as well as the company's network of “Dexcom Warriors.” Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

With a number of late-breaking presentations and high-profile phase 2 and 3 trials, the 2025 American Diabetes Association (ADA) Scientific Sessions reflect how rapidly the treatment landscape for obesity and diabetes is evolving. This year's meeting, held June 20–24 in Chicago, will showcase significant updates on combination therapies, once-weekly insulin regimens, and novel mechanisms that may redefine standards of care for both type 1 and type 2 diabetes. Among the highlights: new efficacy and safety data for GLP-1–based therapies, novel amylin analog combinations, and once-monthly treatment options signal a shift toward personalization and convenience in metabolic care. In this special episode of Diabetes Dialogue cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, preview the most anticipated data, explore clinical implications, and discuss what may come next in the exciting pipelines for diabetes and obesity. During the meeting, Isaacs will also participate in a debate on over-the-counter continuous glucose Monitoring with David Ahn, MD, of Hoag, on Friday, June 20, and Bellini will chair 2 sessions, “Real-World Automated Insulin Delivery System Results” on June 20, and “Advances and Trends in Diabetes Technology” on June 22.

In this episode of Diabetes Dialogue, cohostsDiana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, examine a newly released American Diabetes Association (ADA) consensus report titled Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People with Diabetes: The Need for Screening and Early Intervention. The publication emphasizes the importance of recognizing MASLD as a critical comorbidity in individuals with type 2 diabetes and prediabetes and outlines guidance for clinicians to improve early detection, risk stratification, and treatment strategies. The episode begins by placing MASLD in historical context alongside other comorbidities such as cardiovascular disease, chronic kidney disease, and hypertension. The hosts explain that MASLD, previously referred to as nonalcoholic fatty liver disease or NAFLD, reflects a metabolic-driven pathology and is now better understood as a progressive condition that increases the risk of cirrhosis, liver transplantation, cardiovascular disease, and impaired quality of life. The more advanced form, MASH (Metabolic dysfunction-associated steatohepatitis), represents progression toward hepatic fibrosis and cirrhosis. A major focus is the Fibrosis-4 (FIB-4) score, a noninvasive, cost-effective screening tool calculated from common laboratory tests (platelets and liver function markers) to assess fibrosis risk. The consensus report advises routine FIB-4 scoring in adults with type 2 diabetes, particularly those with central obesity. Based on risk thresholds, further evaluation may involve transient elastography (FibroScan), advanced imaging, or hepatology referral. The hosts commend the ADA for offering a clear clinical algorithm for evaluation and referral, as well as pharmacotherapy recommendations tailored to disease severity. For individuals with early-stage fibrosis, lifestyle modification and diabetes therapies such as GLP-1 receptor agonists (eg, semaglutide) are first-line approaches. For advanced fibrosis (F2–F3), resmetirom is the only currently approved treatment for MASH. The report also highlights complications from hepatic dysfunction—including impaired hypoglycemia awareness and sarcopenia—underscoring the broader metabolic impact of MASLD. Isaacs and Bellini stress that MASLD should be approached with the same clinical rigor as other diabetes-related complications. They recommend integrating automated FIB-4 scoring in EHRs, interdisciplinary collaboration with hepatology, and clinician education using decision tools from the consensus report. Reference: Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. Published online May 28, 2025. doi:10.2337/dci24-0094

In this episode of Diabetes Dialogue, co-hosts hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss significant developments in diabetes care from May 2025, including Medtronic's restructured business model, Sequel Twiist's technological collaboration with Abbott, and Breakthrough T1D's efforts to advance early detection of type 1 diabetes (T1D) through national screening initiatives. The discussion opens with news of Medtronic's decision to spin off its diabetes division into a standalone entity, currently referred to as “New Diabetes Company.” While the final name is forthcoming, the move is intended to streamline operations and accelerate innovation within the diabetes space. The hosts highlight the company's promising technology pipeline, including the forthcoming 800 series insulin pump with full smartphone control and plans for a tubeless insulin delivery system. Both experts express optimism that the independence may foster greater agility in product development, enhance accessibility, and maintain a focus on user-centered design, including for populations with visual impairments. Next, Isaacs and Bellini examine the announcement of the Sequel Twiist partnership with Abbott to integrate continuous ketone monitoring (CKM) into a hybrid sensor, which is expected to function similarly to the FreeStyle Libre 3. This device, still in development, will provide real-time data on both glucose and ketone levels—a critical advance for people with type 1 diabetes using insulin pumps, who are at elevated risk for diabetic ketoacidosis (DKA). While excited about the potential for earlier DKA detection, Bellini emphasizes the importance of cost-effective implementation and integration with existing pump platforms. The episode concludes with coverage of Breakthrough T1D's advocacy before the US Preventive Services Task Force to support routine screening for T1D autoantibodies. The goal is to identify individuals in early stages of the disease to prevent DKA and misdiagnosis. The hosts note that despite advancements in understanding T1D progression, many patients remain undiagnosed until presenting with DKA or are mistakenly classified as having type 2 diabetes. References: Medtronic plc. Medtronic announces intent to separate Diabetes business. Medtronic News. Published May 21, 2025. Accessed June 2, 2025. https://news.medtronic.com/2025-05-21-Medtronic-announces-intent-to-separate-Diabetes-business Sequel Med Tech. Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott's Future Dual Glucose-Ketone Sensor. GlobeNewswire News Room. Published May 22, 2025. Accessed June 2, 2025. https://www.globenewswire.com/news-release/2025/05/22/3086535/0/en/Sequel-Med-Tech-to-Integrate-twiist-Automated-Insulin-Delivery-AID-System-with-Abbott-s-Future-Dual-Glucose-Ketone-Sensor.html Breakthrough T1D. Breakthrough T1D Submits Application to Make Screening for Type 1 Diabetes Part of Recommended Preventive Services in the US - Breakthrough T1D. Breakthrough T1D. Published May 21, 2025. Accessed June 2, 2025. https://www.breakthrought1d.org/for-the-media/press-releases/breakthrough-t1d-submits-application-to-make-screening-for-type-1-diabetes-part-of-recommended-preventive-services-in-the-us/

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, are joined by Roy Beck, MD, PhD, executive director of the Jaeb Center for Health Research, to discuss the INHALE-3 trial, an adult study evaluating technosphere inhaled insulin (Afrezza) in comparison to standard diabetes therapies, including automated insulin delivery (AID) systems. Beck outlined his center's transition from ophthalmology-focused research to becoming a key player in diabetes trials over the last 25 years, particularly in technology-driven therapies. The conversation explores inhaled insulin's pharmacokinetic profile—its rapid onset and short duration, which more closely mimics physiologic insulin responses than injected rapid-acting analogs. The INHALE-3 trial randomized adults with type 1 diabetes (T1D), including nearly 50% who were on AID systems, to either continue their current regimen or switch to once-daily insulin degludec plus Afrezza for meals and corrections. Surprisingly, Beck highlighted participants willing to suspend AID use to try the inhaled approach, allowing for a head-to-head comparison. The study met its primary non-inferiority endpoint for HbA1c, with outcomes from Afrezza plus basal insulin comparable to those achieved with AID and multiple daily injections. However, Beck emphasized the heterogeneity in response. Approximately 30% of participants switching to Afrezza achieved notably better glycemic control (including greater reductions in HbA1c and less time >250 mg/dL), while a similar proportion performed worse, largely depending on their engagement and dosing frequency. CGM use was required in the study, enabling patients to re-dose Afrezza postprandially as needed, a key factor in those who succeeded. Beck also indicated that overnight glycemic control remained a challenge. While Afrezza performed well during daytime periods, AID systems outperformed it overnight—an expected finding given AID's strength in basal modulation. Weight gain was also lower in the Afrezza group, offering an additional potential advantage. Hosts discussed real-world use cases combining AID with Afrezza, with Beck sharing his son's personal success using Afrezza alongside Tandem Diabetes' Control-IQ in sleep mode, a workaround to prevent algorithmic overlap. He noted future integration could be more seamless with upcoming Bluetooth-enabled Afrezza inhalers or AID systems capable of receiving inhalation data. Safety data showed bronchospasm was rare in the trial, with no confirmed cases attributable to Afrezza. Cough was the most common side effect, generally mild and transient, while active asthma and smoking remained contraindications. Isaacs and Bellini highlighted Afrezza's potential as an underutilized but powerful option in the diabetes toolkit, particularly for patients seeking alternatives to injections or pumps, or looking for greater control over postprandial excursions. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Chapters 00:00:01 Introduction and Background of Dr. Roy Beck 00:02:16 Overview of Inhaled Insulin 00:06:31 INHALE-1 Pediatric Study 00:07:21 INHALE-3 Adult Study 00:11:18 Study Results and Participant Outcomes 00:19:57 Challenges and Future Directions 00:26:44 Side Effects and Safety Concerns 00:31:09 Conclusion and Final Thoughts

If you've ever googled a specific insulin pump or CGM, you may well have come across Nerdabetic's content online. His insightful but fun YouTube videos break down the latest and greatest in diabetes technology, helping people with diabetes to understand how they could benefit.In this episode I'm chatting to Kamil Armacky - the real Nerdabetic. We discuss his personal journey into technology after he was diagnosed with type 1 diabetes in 2012, how he went from his first Facebook post to meeting royalty in the name of type 1 diabetes, and how his content - and the impact his content having - has evolved since he started posting eight years ago.Offering personal stories as well as practical tips for the tech-curious, Kamil reveals his top tips for figuring out what insulin pump might work for you, what the diabetes CEOs really think, why the time in happiness is just as important as time in range - and how he ended up serving undercooked chicken on Junior Masterchef...CONNECT WITH KAMILFollow Nerdabetic on Instagram.Subscribe to his YouTube channel.Follow Nerdabetic on X.JOIN THE TYPE 1 ON 1 INSTAGRAM COMMUNITYCome and say hi @studiotype1on1 on Instagram. SPONSOR MESSAGE This episode of Type 1 on 1 is sponsored by Insulet, the makers of Omnipod tube-free insulin pump therapy. Using Omnipod 5 Automated Insulin Delivery has improved my diabetes management significantly with less diabetes decisions, and of course no multiple daily injections.  How? Well, Omnipod 5 automatically adjusts insulin every five minutes to help keep me in range, allowing life outside of type 1 diabetes to get bigger. If you want to know more, head to Omnipod.com.

Video Version Only on HCPLive! In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, sit down with Steven Russell, MD, PhD, Chief Medical Officer at Beta Bionics, to discuss the latest real-world outcomes from the iLet Bionic Pancreas—an autonomous insulin delivery (AID) system cleared by the US Food and Drug Administration (FDA) in 2023. Russell outlines the iLet's fully automated design, which sets it apart from conventional AID systems by requiring no manual settings, carb ratios, or correction factors. The system determines 100% of insulin dosing, adapting continuously to glycemic trends without relying on user engagement. This autonomy makes the iLet particularly effective for individuals with suboptimal diabetes self-management or limited access to endocrinology care. New real-world data, covering 3,300 users from the first year of commercial rollout, reveal a mean baseline A1c of 8.5%—higher than the 7.8% in the pivotal trial and reflective of the broader U.S. type 1 diabetes (T1D) population. The iLet reduced glucose management indicator to 7.3%, yielding an average A1c reduction of 1.2%, more than double that seen in the pivotal study. Outcomes were most pronounced among those with severe hyperglycemia: users starting with A1c >14% saw average reductions of 7%, with low rates of diabetic ketoacidosis (DKA) and minimal increases in hypoglycemia (median time

This week on The Huddle, we're resharing an episode from last summer featuring Kristine Batty, PHD, APRN, BC-ADM, CDCES, FADCES as she discusses her experience both living with Type 1 diabetes and working with people with diabetes as a certified diabetes care and education specialist. She shares the importance of putting yourself in your client's shoes in order to understand their goals and pain points and support their needs, especially when it comes to diabetes technology.Visit danatech here: danatech l Diabetes Technology Education for Healthcare ProfessionalsLearn more about the latest developments in T1D screening here: T1D ScreeningView Kristine's video series below:https://www.youtube.com/watch?v=HPqraDx-aQwhttps://www.youtube.com/watch?v=SBYpv3LuzBwhttps://www.youtube.com/watch?v=otRUIrx6FkIhttps://www.youtube.com/watch?v=uDrDSSK99-A Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Video Version Only on HCPLive! Key Episode Timestamps 00:00:05 Introduction and Background of Luna Diabetes 00:02:27 Overview of Luna and Its Unique Features 00:04:58 Details of Luna's Functionality and User Experience 00:14:24 Clinical Trials and Feasibility Study Results 00:20:49 Potential Applications and Future Directions 00:24:54 Conclusion and Final Thoughts In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, sit down with John Sjölund and Jon Brilliant, co-founders of Luna Diabetes, to explore their novel approach to automated insulin delivery (AID) designed specifically for individuals with diabetes using insulin pens. The discussion introduces Luna, a small, wearable overnight patch pump that delivers automated insulin microdoses during sleep, addressing one of the most persistent gaps in diabetes care: nighttime glucose variability. Unlike traditional AID systems that require full-day pump use, Luna is built for simplicity and intermittent use. It integrates with any continuous glucose monitor (CGM), requires no input on insulin type, and adapts automatically without user-programmed settings. The system supplements a patient's existing basal insulin, providing algorithm-driven microdoses of rapid-acting insulin at night. The device operates with minimal user interaction—patients fill the pod with up to 10 units of insulin, apply it before bed, and remove it in the morning. Preliminary data from Luna's feasibility study showed promising results: an average 10% increase in time-in-range and a 15% reduction in time spent above 250 mg/dL, without increased hypoglycemia. The ongoing pivotal trial, enrolling 120 participants with type 1 diabetes (T1D), aims to further evaluate safety, efficacy, and patient-reported outcomes, particularly sleep quality, across 13 weeks.  Sjölund and Brilliant emphasized Luna isn't designed to match the full clinical performance of traditional AID systems, but rather to expand access by lowering barriers—providing improved overnight control and reducing cognitive and emotional diabetes burden, especially for those who prefer to avoid pumps. Isaacs and Bellini highlighted Luna's potential not only for people with type 1 diabetes but also for those with type 2 diabetes (T2D), particularly in conjunction with GLP-1 therapies or for patients early in their insulin journey. Luna's no-training-required model could also enable broader adoption in primary care settings, where most diabetes management occurs. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! Full results from the SURMOUNT-5 trial show tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide 2.4 mg (Wegovy) in adults with obesity, according to findings published in The New England Journal of Medicine and presented at the 32nd European Congress on Obesity. “The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management,” said principal investigator Louis J. Aronne, MD, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, in a press release. The phase 3b trial enrolled 751 participants across 32 US and Puerto Rican sites, with 750 receiving at least one dose of study drug. Participants were randomized to their maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg). The primary endpoint was percent change in body weight at 72 weeks. Results showed tirzepatide produced a 20.2% average reduction in body weight versus 13.7% with semaglutide, a 6.5-point difference (P

Video Version Only on HCPLive!  In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down new key updates on cotntinous glucose monitoring (CGM) systems for diabetes, incuding the Dexcom G7, Libre App, and Medtronic Simplera Sync. Dexcom G7 15 Day CGM On April 10, 2025, the FDA granted clearance to the Dexcom G7 15-day continuous glucose monitoring (CGM) system for individuals aged 18 years and older with diabetes. The G7 CGM now boasts the longest-lasting CGM system with 15.5 days of wear and best-in-class accuracy with a mean absolute relative difference (MARD) of 8.0%. Isaacs and Bellini discussed the sensor life of the G7 CGM, with Dexcom announcing only 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days. Abbott Libre App With the launch of the new Libre app, Abbott is replacing the Libre 2 and 3 apps with a new all-in-one app that works with all Libre sensors. With the upcoming discontinuation of Libre 2 and 3 (non-Plus) sensors in the US by September 2025, intermittent scanning will be phased out, improving data continuity and aligning with American Diabetes Association (ADA) recommendations. They also highlight Libre's new integration with Glooko, allowing direct data syncing via Bluetooth from the app. This streamlines clinical workflows, supports EHR integration, and includes features like voice-activated carb logging, reducing both patient and provider burden. Medtronic Simplera Sync On April 18, 2025, the FDA approved Medtronic's Simplera Sync sensor for use with its MiniMed 780G insulin delivery system, expanding CGM options for users. The new all-in-one, fingerstick-free sensor offers simplified insertion and enhanced user flexibility while maintaining compatibility with the system's Meal Detection™ technology and adaptive insulin algorithm. A limited US launch is planned for fall 2025. Isaacs and Bellini noted this long-awaited update could improve access and uptake in the US., especially for newly diagnosed patients, thanks to easier usability and compatibility with Medtronic's strong insulin delivery algorithm. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Key Episode Timestamps 00:00:30 Dexcom G7 15-Day Sensor Approval 00:02:11 Challenges with Sensor Lifespan 00:06:00 Education and Replacement Process 00:09:27 Accuracy and FDA Approval Details 00:11:37 Libre's New Mobile App 00:16:55 Integration with Gluco 00:19:41 Medtronic's Simplera Sync Approval 00:23:03 Future Collaborations and Algorithms 00:28:05 Final Thoughts and Wrap-Up

Video Version Only on HCPLive! In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down new Phase 3 data from the ESSENCE trial examining semaglutide 2.4 mg (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis. With results published in The New England Journal of Medicine, hosts are joined by first author Arun J. Sanyal, MD, director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, to discuss key takeaways from part 1 of the ESSENCE trial, semaglutide's impact on liver outcomes and weight loss, and what the data could mean for the future of MASH treatment. ESSENCE Once-weekly semaglutide 2.4 mg significantly improved liver outcomes in patients with metabolic dysfunction–associated steatohepatitis (MASH) and stage 2 or 3 fibrosis, according to findings from the ESSENCE trial. In part 1 of the ongoing, double-blind, placebo-controlled trial, 800 patients were evaluated at 72 weeks for two primary endpoints: resolution of steatohepatitis without worsening fibrosis, and fibrosis improvement without worsening steatohepatitis. Spanning 253 sites in 37 countries, the full trial enrolled 1197 biopsy-confirmed patients between May 2021 and April 2023. At the interim analysis, semaglutide achieved both primary endpoints. Resolution of steatohepatitis without fibrosis worsening occurred in 62.9% of patients receiving semaglutide compared with 34.3% in the placebo group (difference, 28.7%; 95% CI, 21.1–36.2; P

Video Version Only on HCPLive! In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss the newly published findings from the CATALYST trial, a prospective, observational study establishing the prevalence of hypercortisolism among individuals with difficult-to-control type 2 diabetes (T2D). CATALYST enrolled 1057 adults with T2D and suboptimal glycemic control (HbA1c, 7.5–11.5%) despite treatment with ≥2 glucose-lowering agents. All participants underwent a 1-mg overnight dexamethasone suppression test (DST), and common confounders were excluded. Hypercortisolism—defined as a post-DST cortisol level >1.8 µg/dL—was identified in 23.8% of participants, with even higher rates among those with cardiac disease (33.3%) or on ≥3 antihypertensives (36.6%). Adrenal imaging revealed abnormalities in about one-third of affected individuals. Isaacs and Bellini emphasized how striking it is that such a high proportion of patients met criteria for hypercortisolism, a condition historically considered rare. The trial challenges that perception, revealing that clinical features like persistent hyperglycemia and hypertension—despite optimized therapy—could reflect underlying endocrine dysfunction. They noted that neither A1c nor body mass index (BMI) alone predicted elevated cortisol, although medication intensity and comorbid conditions did. The conversation explored how the recognition of hypercortisolism could alter clinical management. Future studies will assess whether targeted treatments—such as cortisol-lowering pharmacotherapy, including mifepristone (Korlym), or adrenal surgery—can reduce medication burden, improve glycemic control, and lower cardiovascular risk. Isaacs and Bellini pointed out that many patients with hypercortisolism present without the classic phenotype, underscoring the importance of broader screening criteria. Looking ahead, they called for greater awareness among clinicians to consider screening in patients on intensive diabetes and blood pressure regimens who still fail to reach therapeutic goals. Identifying and treating hypercortisolism could open a new pathway to improving outcomes in this population. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Key Episode Timestamps 00:00:01 Catalyst Trial Overview and Introduction 00:01:37 Patient Criteria and Initial Findings 00:04:18 Implications and Next Steps 00:05:23 Adrenal Imaging and Cardiac Disorders 00:07:22 Clinical Implications and Future Research 00:09:13 Demographic Differences and Future Directions

Registration is open now for ADCES25 taking place August 8-11 in Phoenix, AZ! Our conference planning chair Christina Whitehouse, RN, MSN, APRN, ARNP, FADCES, CDCES, shares what to look forward to at this year's conference, and why ADCES' annual conference is the place to be for all diabetes care and education specialists and other professionals in the diabetes space. Register for this year's annual conference at ADCES 2025 Annual MeetingExplore all there is to see in Phoenix at Roosevelt Row Arts District | Downtown Phoenix Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Video Version Only on HCPLive! In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss the top-line results from the ACHIEVE-1 trial evaluating orforglipron—an investigational, once-daily oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) developed by Eli Lilly—for adults with type 2 diabetes (T2D) inadequately controlled by diet and exercise. Isaacs and Bellini emphasized the clinical significance of orforglipron's Phase 3 data in the ACHIEVE-1 trial, which demonstrated substantial reductions in A1c (1.3–1.6%) from a baseline of 8.0% and notable weight loss averaging 16 pounds (7.9%) at the highest dose over 40 weeks. Impressively, more than 65% of participants achieved an A1c below 6.5%, meeting the American Diabetes Association (ADA)'s target for diabetes control. The hosts highlighted the convenience advantage of orforglipron compared to oral semaglutide, which has strict dosing requirements. Oral orforglipron can be taken without food or water restrictions, potentially increasing adherence and reducing treatment burden. They also noted the drug's favorable safety profile, with gastrointestinal side effects similar in type and incidence to existing GLP-1 RAs, and no hepatic safety signals observed in the trial. Beyond glycemic control, Isaacs and Bellini discussed the broader implications for obesity treatment, pointing to the drug's potential utility in weight management, pending regulatory submission. They explored the possibility of using injectable GLP-1 RAs for initial weight loss followed by oral maintenance with orforglipron—potentially lowering costs and improving access. The conversation touched on the upcoming ACHIEVE trial series, which will explore orforglipron in head-to-head comparisons with other agents, its use in insulin-treated T2D, and future indications including cardiovascular risk and kidney disease. While optimistic, the hosts stressed the need for cardiovascular outcomes data to confirm orforglipron's safety and potential benefits in this domain. If confirmed, they suggested orforglipron could become a cornerstone oral therapy for T2D and obesity. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Key Episode Timestamps 00:00:01 Discussion on OR for GLP-1 Receptor Agonist 00:02:13 Potential Impact and Patient Preferences 00:03:59 Safety and Market Potential 00:05:13 Cost and Transition Options 00:06:32 Future Trials and Side Effects 00:08:55 Cardiovascular Outcome Data and Conclusion

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, are joined by Rifka Schulman-Rosenbaum, MD, director of inpatient diabetes at Long Island Jewish Medical Center and co-author of Establishing Screening Programs for Pre-symptomatic Type 1 Diabetes: Practical Guidance for Diabetes Care Providers, a new paper in the Journal of Clinical Endocrinology and Metabolism. With Bellini as a co-author of the piece, experts explored the increasing clinical and operational momentum behind screening for pre-symptomatic type 1 diabetes (T1D) and what it takes to implement effective programs in real-world settings. The conversation centers on the rationale and logistics behind identifying individuals in stages 1 and 2 of T1D—autoimmune stages characterized by multiple islet autoantibodies before clinical onset. With the availability of teplizumab (Tzield), a disease-modifying therapy shown to delay progression to stage 3 of T1D, the importance of early detection and standardized screening protocols has become more urgent. Schulman-Rosenbaum outlined how her work on the JDRF Breakthrough T1D initiative led to the development of actionable guidance aimed at frontline diabetes care providers. She highlights barriers to implementation—such as limited provider awareness of T1D staging and screening protocols—and details her institution's ongoing efforts to educate primary care clinicians and endocrinologists, including distributing screening handouts and creating streamlined workflows using dot phrases and dedicated follow-up slots. The discussion emphasizes targeted screening for high-risk groups, such as first- and second-degree relatives of individuals with T1D and patients with autoimmune diseases like Hashimoto's or celiac. Schulman-Rosenbaum emphasized the opportunity for endocrinologists to screen these patients directly during routine care and the utility of a centralized handout to guide test ordering and family engagement. Drawing from their paper, experts outlined practical steps for launching autoantibody screening programs: nominating a program champion, forming an implementation team, and embedding screening into existing clinical systems. Experts stressed the importance of using appropriate ICD-10 codes for insurance coverage and referenced a diagnostic coding table in their publication. Schulman-Rosenbaum also addressed the widespread issue of misdiagnosis, particularly in adults mistakenly classified as having type 2 diabetes, and outlines best practices for using antibody and C-peptide testing to refine diagnosis. She detailed her hospital's approach to inpatient screening, noting an increased use of autoantibody testing and follow-up coordination for patients with suspected T1D or latent autoimmune diabetes in adults (LADA). Finally, the episode highlighted how to monitor individuals who test positive for a single antibody or exhibit mild dysglycemia, noting that many fall outside established risk categories. Experts called for more research in this area and advocate for individualized monitoring strategies based on clinical risk, family history, and emerging glucose patterns—often using continuous glucose monitoring (CGM) data. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Key Episode Timestamps 00:00:00 Introduction 00:02:18 Inspiration Behind the Paper 00:04:12 Challenges in Implementing T1D Screening 00:07:32 Educating Providers and Overcoming Barriers 00:09:32 Addressing Misdiagnosis of Diabetes 00:12:01 Inpatient Screening Practices 00:16:13 Support and Resources for Patients with Positive Antibodies 00:20:01 Conclusion and Final Thoughts

In the first episode in a multi-part diabetes technology series, Kathryn Evans Kreider DNP, FNP-BC, BC-ADM, FAANP, joins The Huddle to discuss integrating diabetes technology into primary care. She talks about the importance of embracing digital technology in primary care and how health care professionals in primary care can take tangible steps to better utilize the technology available to them.Learn about the latest advances in diabetes technology on danatech:  Diabetes technology for healthcare professionals | DanatechCheck out the two-part Integrating Diabetes Technology into Primary Care course here: Part 1: Integrating Diabetes Technology into Primary Care Part 1: Overview and Clinical ScenariosPart 2: Integrating Diabetes Technology into Primary Care Part 2: Interactive Case Studies   Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

If I take Ozempic, Wegovy, Mounjaro, Zepbound, or any other GLP-1 weight loss drug, will I need to take it forever? What are the side effects of Ozempic? Do we know the long term effects of these weight loss drugs?Can Ozempic be prescribed for women in perimenopause or menopause? What can women do to create sustainable weight loss? How can we lose the weight and keep it off?Diana Isaacs, an endocrinology clinical pharmacy specialist answers the questions above and many others, as they pertain to the safety, sustainability and effectiveness of GLP-1 drugs. Diana serves as the Co-Director of Endocrine Disorders in Pregnancy and the Director of Education and Training in Diabetes Technology at the Cleveland Clinic Endocrinology and Metabolism Institute.From this educational conversation, I learned that certain GLP-1 medications can be used to lower blood pressure, help with cardiovascular disease, kidney disease, and sleep apnea!To be connected with Diana Isaacs, please email Vera Kessler, host of America's Top Rebbetzins at atrebbetzins@gmail.com

On our latest episode of The Huddle, Sheetal Shah, founder of MettaHealth Partners discusses the evolving realm of AI, the role DCESs and other health care professionals can play in embracing and adopting AI technology, and the importance of keeping a human element in the technology.Learn more about MettaHealth Partners here: MettaHealth PartnersLearn more about the National Institute of Standards and Technology (NIST) here: National Institute of Standards and TechnologyStay up to date on all things related to diabetes technology on danatech: Diabetes technology for healthcare professionals | Danatech Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sana announces beta cell transplantation without the need for immunosuppresion drugs, Modular Medical teams up with Nudge BG for a brand new completely closed-loop system, the FDA moves forward to crack down on compounded Ozempic and Mounjaro, Dexcom and Abbott bury the legal hatchett for a while, and more.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:     Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Big news from Sana Biotechnology. Their first in human study of islet cells without any immunosuppression appears to be a success. This is very early and hasn't yet been peer reviewed and published.. but after four weeks, there were no safety issues and the transplanted beta cells were producing insulin. Sana's CEO says  “As far as we are aware, this is the first study showing survival of an allogeneic transplant with no immunosuppression or immune-protective device in a fully immune competent individual. Safe cell transplantation without immunosuppression has the potential to transform the treatment of type 1 diabetes and a number of other diseases.”   I've reached out to Sana to get more on this.. love to talk to them soon.   https://www.bakersfield.com/ap/news/sana-biotechnology-announces-positive-clinical-results-from-type-1-diabetes-study-of-islet-cell/article_d0390fd6-99cb-53bd-b04d-9337121e01bf.html XX FDA says no for sotagliflozin as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).  Studies showed a meaningful reduction in A1C but a meaningful increase in DKA. The FDA first rejected this in 2019 and was resubmitted last summer. But The advisory committee voted 11 to 3 against the approval of sotagliflozin stating that the benefits of sotagliflozin do not outweight the risks in adults with T1D and CKD. Sotagliflozin is currently approved under the brand name Inpefa to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with 1) heart failure; or 2) type 2 diabetes mellitus, CKD, and other cardiovascular risk factors.  According to Lexicon, Inpefa will continue to be manufactured and made available to patients. https://www.renalandurologynews.com/news/fda-denies-approval-of-zynquista-for-type-1-diabetes-and-ckd/ XX Two companies we've been following are teaming up.. Modular Medical has an FDA clear patch pump and Nudge BG has an adaptive full closed loop. They've announced a new partnership agreement. From the release: Modular Medical's easy-to-use and cost-effective MODD1 insulin pump technology. Our combined system is intended to nudge blood glucose by making small changes to insulin delivery based on estimated glucose inputs from a continuous glucose monitor." Familiar name to some of you, Lane Desborough is the founder of Nudge BG. He says this will be a fully automated system, no mealtime bolusing needed.   https://www.accesswire.com/957703/modular-medical-announces-licensing-and-partnership-agreement-with-nudge-bg XX Beta Bionics filed for an initial public offering on Monday. The company did not disclose the number of shares it will offer or the price range. Beta Bionics plans for shares to be listed on the Nasdaq under the ticker symbol “BBNX.” The Irvine, California-based company makes an insulin pump called the iLet Bionic Pancreas, which was cleared by the Food and Drug Administration in 2023. Beta Bionics plans to use the proceeds to grow its sales and manufacturing infrastructure and develop new features for its device.   https://www.medtechdive.com/news/beta-bionics-insulin-pump-files-ipo/736805/     XX Tandem Diabetes Care, Inc. signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems.   There's a long history here – UVA is where the Control IQ algorithm was developed.  This agreement seems to keep the team together for another decade. https://www.businesswire.com/news/home/20250107162995/en/Tandem-Diabetes-Care-Enters-Multi-Year-Research-Collaboration-with-UVA-Center-for-Diabetes-Technology-for-Development-of-Advanced-Insulin-Delivery-Systems XX New study says insulin is still the best treatment for gestational diabetes, compared to oral glucose-lowering medications. Metformin and gluburide are being closely looked at since they're easier to administer, less costly, and have better acceptance among patients. But this study says insulin was a bit better – slight more babies were born larger for the metformin group, and more moms had hypoglycemia. https://www.medpagetoday.com/obgyn/pregnancy/113651 XX In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, the type 2 diabetes injection it sells as Victoza. Novo Nordisk last month filed a Citizen Petition with the FDA asking the federal agency to exclude its type 2 diabetes injection Victoza (liraglutide) from a proposed list of drugs eligible for compounding. https://www.biospace.com/fda/novo-launches-citizen-petition-to-block-compounded-victoza XX Bit of an update on compounded terzepatide and semaglutide. The FDA is allowing a grace period of 60 days before starting to enforce the end of allowing compounds of Mounjaro. Meanwhile, semaglutide remains on the FDA's shortage list for several dose strengths, though all doses have been reported as “available” since late October 2024. Compounding pharmacies, especially larger 503B “outsourcing facilities,” maintain they provide an essential public service by offering lower-cost versions of medications that can cost over $1,000 per month. Many insurers still refuse to cover brand-name GLP-1 products for weight loss. Yet  the FDA has reported hundreds of adverse event reports allegedly linked to compounded versions of these drugs, which do not undergo the same rigorous manufacturing inspections and clinical testing as approved brands.   https://www.drugdiscoverytrends.com/compounders-and-drugmakers-clash-over-compounded-weight-loss-drugs-with-fda-in-the-middle/ XX Interesting story here.. this study says a fecal transplant can help people with type 1 and severe gastroenteropathy. The researchers say diabetic gastroenteropathy commonly affects individuals with type 1 diabetes, causing debilitating symptoms like nausea, vomiting, bloating, and diarrhea; however, treatment options remain limited. Researchers conducted a novel clinical trial to test the benefits of FMT in adult patients with type 1 diabetes and severe symptoms of gastroenteropathy, who were randomly assigned to receive either FMT or placebo capsules as the first intervention. After four weeks, Compared with placebo, FMT led to significant changes in the diversity of the gut microbiome. https://www.medscape.com/viewarticle/fmt-shows-early-success-type-1-diabetes-bowel-issues-2025a10000bg XX A couple of weeks ago, listeners told me that the Dexcom geofencing issue we reported on seems to be resolved. Dexcom is now confirming this. Previously, if you had an issue with Dexcom G7 outside of your home country, you couldn't reinstall or use the app without customer support. As of last month, the geofencing issue has now been resolved with the latest Dexcom G7 2.6 app update. Can I travel with my Dexcom G7? | Dexcom XX Abbott and Dexcom settled all patent lawsuits related to continuous glucose monitors (CGMs). The two competitors, who lead the U.S. market for CGMs, agreed on Dec. 20 to resolve all outstanding patent disputes and not sue each other over patents for 10 years.   Dexcom and Abbott previously reached a settlement in 2014 related to their diabetes devices, which included a cross-licensing deal and an agreement not to sue each other until 2021. After that agreement expired, the companies filed a volley of patent lawsuits. https://www.medtechdive.com/news/abbott-dexcom-settle-cgm-patent-lawsuits/736300/  

During a special episode of The Huddle recorded live at our 2024 annual meeting, we sat down with incoming ADCES President Veronica Brady, PhD, FNP-BC, BC-ADM, CDCES, FADCES. Veronica discussed the impact she wants to leave behind as President this coming year, as well as the concept of unconscious bias, how it shows up in our everyday lives and in working as health care professionals, and how we can practice cultural humility to better serve the needs of people with and at risk for diabetes. Please note: since the recording of this episode, Kirsten Yehl has since moved on from ADCES to pursue another professional opportunity. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Today, we're diving into the intersection of diabetes and the healthcare system with an incredible guest – Natalie Bellini, who brings over 50 years of lived experience with type 1 diabetes and expertise from the forefront of diabetes care. As an Endocrine Nurse Practitioner, Certified Diabetes Care and Education Specialist (CDCES), and Program Director for Diabetes Technology at University Hospitals in Cleveland, Natalie is also the host of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives. Throughout her career, she has been a trailblazer in advancing diabetes care, publishing studies on topics like GLP-1s and groundbreaking diabetes technology, and speaking nationally and globally to advocate for the community. In this episode, we discuss key issues in the doctor-patient relationship and what needs to change, the role of technology in improving outcomes when patients are empowered with education, the challenges many people with type 1 diabetes face, and the critical importance of early screening for type 1.Time Stamps:  (02:58) "Diabetes kind of found me, I didn't find it." (03:30) The Evolution of Natalie's Career (05:57) Being Diagnosed 50+ Years Ago & the Technological Advances Made Since (12:50) How the Education Around T1D and the Complications Have Changed(14:00) Balancing Patient Care with Healthcare System Demands  & The Growing Crisis of T1D Misdiagnosis with Adults. (16:00) Emotional and Psychological Aspects of Diabetes Management(16:41) Barriers to Effective Diabetes Management (19:54) “You should never say you're fine when you walk into an endo's office.”(20:25) Why So Many T1Ds Are Still Struggling (With or Without Technology) (32:00) The Importance of Addressing Emotions in Diabetes Management(34:55) The Truth About AID (40:26) The Importance of Early Detection(41:00) “In the US, they are recommending first-degree relatives be screened and people aren't doing a great job of it because we need to educate the right people.” (42:26) The Science of Understanding Antibodies (52:49) Finding the Support You Deserve What to do now:Follow me @lauren_bongiorno and @riselyhealth on Instagram to stay in the loop when new episodes drop.Doors are open for the January 2025 round of our signature group coaching program. Apply for coaching and talk to our team so you can reclaim the life you deserve. Be ready to treat very low blood sugar with Gvoke HypoPen® (glucagon injection). To find out more, go to GvokeGlucagon.com/RiselySee Important Safety Information: https://www.gvokeglucagon.com/#important-safety-informationSee Full Prescribing Information: https://bit.ly/3baHqAODisclaimer: Nothing you hear on the Reclaim your Rise podcast should be a substitute for personalized professional medical advice. Please always consult your physician or other medical professional before making any changes to your diet, insulin dosages, or healthcare plan. 

Recorded live at ADCES24, we sat down with Jane Jeffrie Seley, DNP, MPH, MSN, GNP, BC-ADM, CDCES, CDTC, FADCES​ to talk about the latest in diabetes technology and what to expect in the coming year, how diabetes technology overall is evolving and changing, and how diabetes technology can more seamlessly be integrated into primary care settings.Please note that this episode was recorded in August and some of the technology and updates discussed in future tense may now be in different stages of development or release. References to specific devices and manufacturers are for educational purposes and do not represent an endorsement from ADCES.Links: Register to view ADCES24 on-demand content: ADCES24 (adcesmeeting.org)Find up-to-date diabetes technology product information, device training, professional education and more on danatech: Diabetes technology for healthcare professionals | Danatech (adces.org)Find your technology competency level and resources to dive deeper with our tech competency tool: Technology Competency Finder| Danatech (adces.org)To learn more about the latest and greatest in diabetes technology, register for our Diabetes Technology Conference: Diabetes Technology Conference 2024 (eventscribe.net)To take a deeper dive into the integration of diabetes technology in primary care by checking out this two-part course developed in partnership with the American Association of Nurse Practitioners (Made possible thanks to a grant from Helmsley Charitable Trust).:Part 1: Integrating Diabetes Technology into Primary Care Part 1: Overview and Clinical Scenarios (0.75 CE/CME)Part 2: Integrating Diabetes Technology into Primary Care Part 2: Interactive Case Studies (1 CE/CME)Learn more about the PANTHER Program: Diabetes Technology. Deciphered. | PANTHER ProgramVisit diatribe: Making Sense of Diabetes | DiaTribeVisit the Medical Professional's Reference website: Prescription & OTC Drug Info | Side Effects, Interactions & Dosages (empr.com)Visit the ADA Consumer Guide: ADA Consumer Guide (diabetes.org)Find resources from DiabetesWise: Home » DiabetesWise Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

In this episode of the "We Are T1D" podcast, Mike and Jack share their weekly adventures, bringing laughs and relatable moments for everyone navigating Type 1 Diabetes. Tune in as they discuss Jack's needle, Mike's TikTok success, and a hilarious run-in with a "Karen" in the diabetes community. Whether it's Jack avoiding a carnival or the duo tackling the highs and lows of blood sugar management, this episode offers humor, insights, and valuable tips on living with T1D. Perfect for anyone in the diabetes community looking for laughter and support! 02:09 - Jack Week & Being lazy 04:00 - Mike's Week & Drama 09:09 - Diabetes Admin & Flying 14:27 - The huge spider 17:02 - Time In Range 35:21 - Listener Wins Join the conversation and share your stories with the T1D community. Don't forget to rate, review, and subscribe to help others find the podcast. Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Share your stories at https://wearet1d.com New episodes are released every Sunday & Wednesday PS. If you would like to be a guest on the podcast, please go to the website https://wearet1d.com/guest-booking and fill out the form. Stay tuned for more listener stories and community wins!  

This week on The Huddle, we're resharing an episode with Miguel Johns, Co-Founder & CEO of mmnt and creator of Milton. Miguel discussed how the use of artificial intelligence (AI) can benefit health care professionals across the diabetes space and how this technology is growing and changing. Topics include addressing some of the current opportunities and challenges associated with AI in health care, how AI can provide improved clinical decision support, and where this technology may be headed in the future.Explore danatech here: Diabetes technology for healthcare professionals | Danatech (adces.org)For more information on Miguel or mmnt, visit Milton | Powered by MMNT (getmilton.com)View a recorded annual conference session on AI and more by registering for ADCES24 On Demand: ADCES24: Diabetes Care, Education and Technology (mcievents.com)Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

As we step back into the episode with Ryan Taylor we touch on his time on Geordie Shore to the unexpected challenges and connections he made along the way, Ryan offers a candid look at the highs and lows of living with diabetes in the public eye. Ryan discusses the intricacies of dealing with type 1 diabetes in high-pressure environments, the misconceptions about the condition, and the importance of community support. He also touches on the impact of social media on diabetes awareness and the often overlooked role of vitamins in managing hypo awareness. Listeners will find inspiration in Ryan's journey, as he balances the demands of his career with the realities of diabetes, all while advocating for a more open and positive dialogue around the condition. 01:19 - Geordie Shore Talk 05:51 - Did you have any seriously bad hypos? 13:30 - Whats your favourite hypo treat? 15:01 - Do you weigh or Guesstimate? 21:10 - Diabetics can be negative 23:58 - Only one in my school 24:32 - Three common medications can cause insulin resistance 29:11 - There's so little focus on actual diabetes 29:54 - Did you see diabetes taking you to where you are now? 34:51 - Ryan says talking about diabetes makes him focus on his own diabetes 37:53 - Contact Info Join the conversation and share your stories with the T1D community. Don't forget to rate, review, and subscribe to help others find the podcast. Follow The Podcast https://www.instagram.com/wearet1d Follow Ryan on Instagram https://www.instagram.com/ryancbtaylor Follow Ryan on TikTok https://www.tiktok.com/@ryant1d Share your stories at https://wearet1d.com   New episodes are released every Sunday & Wednesday   PS. If you would like to be a guest on the podcast, please go to the website https://wearet1d.com/guest-booking and fill out the form.  

Join Maria A. Mogollon, MSN, APRN, FNP-BC, a Diabetes and Obesity Nurse Practitioner and former Internal Medicine physician in Venezuela, and Jeff Unger, MD, FAAFP, FACE, DACD, Director, Unger Primary Care Concierge Medical Group, renowned Board-Certified Family Physician, Diabetologist, and co-author of the AACE 2021 Clinical Practice Guideline for the Use of Advanced Technology in the Management of Persons with Diabetes Mellitus, as they delve into crucial topics in diabetes technology. Key topics discussed include the benefits and cost-effectiveness of continuous glucose monitors (CGM) compared to traditional finger-stick methods, practical implementation into practice workflows, interpreting CGM data, and identifying ideal candidates for CGM use. Through case studies and practical examples, they address common concerns and barriers to CGM adoption, providing valuable insights for healthcare professionals on how to have effective conversations with patients and integrate CGM technology into patient care.

For those with diabetes who use insulin pump therapy, having access to training and education on this technology is key to success. David Jopke, DNP, FNP-C, BC-ADM, CDCES, Tracy Newell RD LD, CDCES, RD, LD, CDCES, Erin L. DaRosa, MBA, RDN, LD, CDCES join The Huddle to talk about their experiences creating a  team-based formal process for becoming an insulin pump trainer, and how practice settings that want to offer insulin pumps and automated insulin delivery system options to people with diabetes can create their own formalized process.Learn more about HealthPartners here: HealthPartners – Top-Rated insurance and health care in Minnesota and WisconsinView danatech's resources on insulin pumps & AID here: Insulin Pumps l diabetes training and education l Danatech (adces.org)Learn more about the Panther program here: Diabetes Technology. Deciphered. | PANTHER Program Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

We know research is crucial for making continued advances in diabetes care for all populations. Rachel Stahl-Salzman, MS, RD, CDN, CDCES, and Kerri Knippen, PhD, RDN, LD, BC-ADM, FAND, join us on The Huddle to talk about their latest research projects related to pregnancy in diabetes, some of the outcomes and learnings of each study, and how diabetes care and education specialists can be leaders in this work, even without a research background.View Rachel's research poster diving deeper into this topic here: Annual QIPS Symposium | Weill Department of Medicine (cornell.edu)Learn more about Kerri's project here: https://www.eeds.com/enduring_material.aspx?AIN=005243415&SIN=230144&Display_Portal_Nav=true https://bsmh.zoom.us/rec/play/dNYY9PJAVNjh_wJCglFQuYOU9GYRTC4JYP1xEr3eqd5037qGu1kvWbgs0Mw35SdAhBtm-W66tyZCnDv8.FBeiYIeEMAKXck4F?canPlayFromShare=true&from=share_recording_detail&startTime=1713455116000&componentName=rec-play&originRequestUrl=https%3A%2F%2Fbsmh.zoom.us%2Frec%2Fshare%2F6jgesPiUBq5EIbX8P7K0pzRJ4yKEb-HPxmBMMhqUZxbBBqREek8OvlNR7vh3aQR2.hQwbtfqHOQ8tp3uF%3FstartTime%3D1713455116000Join the poster presentations at #ADCES24 to learn even more about Kerri and Rachel's work! Learn more and register for the conference here: ADCES24 (adcesmeeting.org)Learn more about the ADCES Foundation here: ADCES Foundation Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Contact the showProfessor Partha Kar has made sure the technical advances in measuring blood sugar are available to everyone living with Type 1 diabetes in the UK.  Partha had to overcame massive hurdles to make sure the technology was not just available to a privileged few. He discusses with Maggie and Andrew his inspirational leadership style and philosophy that have helped him to move mountains in the NHS.Vote for One in Six Billion in the British Podcast Awards: https://www.britishpodcastawards.com/voting

Kristine Batty, APN, BC-ADM, and CDCES talks about her experience both living with Type 1 diabetes and working with people with diabetes as a CDCES, and how understanding both sides of the desk can help to optimize health outcomes. Visit danatech here: Diabetes technology for healthcare professionals | Danatech (adces.org) View Kristine's video series below:Reducing Diabetes Technology Burnout (youtube.com)Continuous Glucose Monitoring: Managing Expectations (youtube.com)Breaking Down Diabetes Technology Barriers (youtube.com)The Essentials of CGM Accuracy (youtube.com) Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

In this episode of the podcast Rob is solo as he interviews Dr. Anath Shalev, a diabetes researcher turned founder of startup Tiximed. Dr. Shalev discusses the discovery of TixnIP, a protein involved in oxidative stress in beta cells, and its potential for treating diabetes. The conversation covers the development of TIX 100, an oral medication targeting TixnIP, its implications for type 1 and type 2 diabetes, and the differences from existing diabetes treatments like SGLT2 inhibitors and GLP-1 agonists. Topics discussed: * Dr. Anas Shalev's background in diabetes research and founding of Tiximed * Discovery of TixnIP and its role in beta cell health * Potential of TIX 100 as a novel oral medication for diabetes treatment * Comparison of TIX 100 with existing diabetes treatments like SGLT2 inhibitors and GLP-1 agonists * Research process behind TixnIP inhibition and development of TIX 100 * Future of diabetes care, combination therapies, and impact on patients' lives * Information about Tiximed, clinical trials, and ways to support the research 00:18  Revolutionizing Diabetes Treatment: From Researcher to Founder 03:47  Revolutionizing Diabetes Treatment: Targeting Beta Cells and Glucagon Levels 13:47  Revolutionizing Diabetes Treatment: Targeting Beta Cells in Type 1 and Type 2 Diabetes 17:35  Revolutionizing Diabetes Treatment with Ticks 100: A Breakthrough in Addressing the Root Cause of the Disease 27:35  The Limitations and Advantages of Verapamil in Diabetes Care 29:47  Advancements in Diabetes Technology and Research: A Look into the Future 33:04  Exploring Diabetes Treatment Innovations with Dr. Shalev Topics discussed: 1. Mila's Personal Journey including leaving her job to focus on Hangry Woman full-time 2. Career Shift and Health Coaching: Transition from a marketer to a health coach 3. Bridging the gap between fear of eating and enjoying meals 4. Importance of Self-Care and Boundaries: Prioritizing self-care to avoid burnout 5. Support System in Content Creation: Managing overwhelm by acknowledging limitations 6. The role of support team members in providing feedback and managing projects 7. Navigating Changes in Diabetes Diagnosis: Transition from type 2 to type 1 diabetes diagnosis 8. Representing Diverse Voices in the Diabetes Community: Importance of diversity representation and transparency in collaborations 9. Kindness, Respect, and Accountability: Impact of chronic illness on behavior and comparison culture 10. Addressing misconceptions about online personas and supporting creators 11. Building a Supportive Diabetes App Key takeaways: * Embracing personal growth amidst challenges and life changes * Prioritizing self-care, setting boundaries, and recognizing emotional well-being * Navigating career shifts and advocating for representation in the diabetes community * Building a supportive community and offering personalized health support through technology * Upholding kindness, respect, and accountability in online interactions and content creation References: * The Hangry Woman * Glucose Guide App 00:00  Celebrating Diabetes Stories Worldwide 00:02  The Evolution of Mila Clarke: Navigating Life Changes and Diabetes Management 04:15  From Marketer to Health Coach: A Journey of Personal and Professional Growth 08:16  Learning to Set Boundaries and Prioritize Self-Care: A Journey of Self-Discovery and Growth 12:16  Navigating Burnout and Building a Support System in Content Creation 17:26  Navigating a Diabetes Diagnosis Change: Impact on Community, Relationships, and Advocacy 23:49  Navigating a New Diagnosis and its Impact on Personal Branding 28:04  Breaking Barriers and Building Bridges in the Diabetes Community 32:36  Debunking Myths and Realities of Being a Successful Black Woman Entrepreneur 42:36  Embracing Kindness and Abundance in a World of Competition 52:36  Navigating Social Media Etiquette and Misconceptions as a Creator 55:53  Navigating Online Criticism and Embracing the Journey to Success in Content Creation 01:02:49  Revolutionizing Diabetes Support with a Unique Pocket Guide App 01:06:10  Empowering Diabetes Management through Personalized Support and Community Connection 01:09:21  Building a Supportive Community Beyond Social Media Platforms 01:14:05  Empowering Health and Support Through a Unique Approach 01:17:12  The Value of Ads and Support in Providing Free Content and Services

Jack kicks things off with his win of the week – celebrating his fifth wedding anniversary with a weekend full of food, drinks, and live music at Pub in the Park. From enjoying performances by Boyzlife and DJ sets by Vernon Kay and Kimberly Wyatt, to indulging in free samples of gin, ale, and snacks, it's a festival experience worth recommending. Mike shares his win of achieving 83% in-range blood sugars for the week, attributing his success to consistent gym sessions and the MyFitnessPal app. The hosts discuss the importance of tracking macros and the benefits of using such apps for managing diabetes. However, not everything is smooth sailing. Jack recounts a frustrating hospital appointment where he felt unfairly criticised for running his blood sugars "too tight." Despite achieving 93% in-range, his nurse focused on the 2% lows, leading to a heated exchange. This discussion highlights the importance of constructive feedback and understanding the lived experience of diabetes. Mike's struggle this week revolves around resisting the temptation of share bags of crisps and popcorn, while Jack introduces a new hypo treat – honey roasted cashews with cinnamon, discovered at the festival. The episode wraps up with the 'Listener Wins' segment, celebrating the community's triumphs, from improved in-range percentages to smashing gym sessions and even winning at crazy golf. Whether you're looking for motivation, a good laugh, or just a sense of connection, this episode has it all. Remember, you're not alone in this – WE ARE T1D! Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Get your wins on the podcast at https://wearet1d.com New episodes go out every Sunday & Bonus On A Wednesday! Don't forget to Subscribe/Follow, Rate, and Review to help others find the podcast and join the T1D community.    

Warning: This episode is not for the faint of heart or those easily offended. It's raw, it's real, and it's a bit naughty. You've been warned. Brace yourselves for the long-awaited and unabashed Part Two of the Jonsel episode on 'We Are T1D' - the podcast that doesn't just talk diabetes, it lives it. Hosts Mike and Jack, the candid voices of Type 1 Diabetes, delve into the gritty, unpolished side of living with T1D, with their guest who's as real as it gets. Jonsel, a man who's not afraid to speak his truth, shares his journey through the entertainment industry, his battle with the highs and lows of diabetes, and the stark reality of managing this chronic condition in the public eye. From the heartache of empty theatres to the frustration with charities, Jonsel's story is a rollercoaster of emotions and experiences that many with T1D can relate to. Get ready for some outrageous hypo tales that will have you in stitches, discussions on the taboo topic of diabetes and sex, and the kind of uproarious banter that only comes from three guys who know how to laugh in the face of adversity And for those who've been touched by Jon's candidness, his books, 'Diabetes Won't Defeat Us' and 'Keep Calm I'm Only Diabetic', are available on Amazon. Plus, don't miss his powerful short film, 'Hypo', on YouTube - a must-watch that sheds light on the silent struggles of living with T1D. Follow Jonsel on Instagram @jonsel99 and join the conversation that's breaking barriers and building bridges in the T1D community. Remember to Subscribe/Follow, Rate, and Review to support the podcast and help spread the word about the real life of living with Type 1 Diabetes. Share your stories, find your tribe, and never forget - you're not alone on this ride. Until next time, keep it real, keep it raw, and keep laughing through the lows. Peace out, and stay syringed! Follow The Podcast https://www.instagram.com/wearet1d Follow Mike https://www.instagram.com/t1d_mike Follow Jack https://www.instagram.com/t1d_jack Get your wins on the podcast at https://wearet1d.com  

Join us as we talk about our experience at the 18th Annual Diabetes Technology Meeting in Europe (ATTD 2024). In this podcast, we'll be unpacking our favorite lectures from the event, which hold some very exciting data and insights. From cutting-edge advancements in diabetes technology to the latest developments in medications, we'll cover it all. Tune in as we explore the forefront of diabetes innovation and share our experiences from this meeting!In this episode, we will talk about:What updates are happening in diabetes technology? What are updates in diabetes medications? What is new with CGMs and Type 2 Diabetes? What is the silence all alert on your Dexcom G7? What is a continuous ketone meter and when is it coming? What is the most common cause of DKA in type 1's? What is time in tight range? What is Tzield (data information)? What is the new data on Afrezza? What is new information about SGLT2 inhibitors? What data information came out regarding Mounjaro? Show notes:Diabetes Technology Podcast - https://tcoydthepodcast.transistor.fm/47TCOYD Video Vault - https://tcoyd.org/tcoyd-video-vault/TCOYD Live PLUS Diabetes Technology https://tcoyd.org/live-feb-2024/?  ★ Support this podcast ★

Diabetes technology is getting better and better. We have automated insulin systems that link pumps and CGMs, and smart insulin pens that have precise calculations and reminders. It's been quite the evolution over the past few years! But outcomes – time in range, A1Cs, aren't exactly where experts thought they might be. I'm talking to Dr. Stephen Ponder about why that is, how a social media post he shared about this caused a strong reaction, and what does work for better long term outcomes. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com